Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermetatarsal Bursitis in Rheumatoid Arthritis
NCT05698563Terminated
- Sponsor
- Rigshospitalet
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Open-label trial in Intermetatarsal bursitis (IMB), sponsored by Rigshospitalet. Primary endpoints: Incidence of intermetatarsal bursitis on MRI at 8 weeks and Incidence of intermetatarsal bursitis on Ultrasound at 8 weeks. Started Jan 2023; status: terminated.
02
Conditions
Intermetatarsal bursitis (IMB)
Beyond the preview
Go deeper on NCT05698563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698563.